Re: Again the sicker NIAID Grade 3 patients
Are you and other ViralClear direct stockholders suggesting to Londoner-Zeldis that a CEO letter or blog on the website be orchestrated soon regarding the expanded trial?
More clarity on the trial and expectations to include better timeframes for the signal to pivot to PIII etc. would change perceptions of this program.
Also, agree more progress on the roll-out of Pure EP...
Appreciate what you and others can do to voice investors concerns...
As an aside, Martha Pease recent Form 4 for 20,000 shares BSGM.